IRIX Logo

IRIDEX Corporation (IRIX) 

NASDAQ
Market Cap
$26.45M
Sector
Healthcare
Industry
Medical—Devices
Rank in Sector
726 of 960
Rank in Industry
88 of 120

Largest Insider Buys in Sector

IRIX Stock Price History Chart

IRIX Stock Performance

About IRIDEX Corporation

IRIDEX Corporation, an ophthalmic medical technology company, provides therapeutic based laser systems, delivery devices, and consumable instrumentation to treat sight-threatening eye diseases in ophthalmology. It offers laser consoles, such as Cyclo G6 laser system for use in the treatment of glaucoma; IQ 532 and IQ 577 laser photocoagulation systems, which are used for the treatment of diabetic macular edema and other retinal diseases; and OcuLight TX, OcuLight SL, OcuLight SLx, OcuLight GL, and OcuLight GLx laser photocoagulation systems …

Insider Activity of IRIDEX Corporation

Over the last 12 months, insiders at IRIDEX Corporation have bought $0 and sold $0 worth of IRIDEX Corporation stock.

On average, over the past 5 years, insiders at IRIDEX Corporation have bought $19,258 and sold $0 worth of stock each year.

There was no buying activity among insiders over the last 12 months.

The last purchase of 2,000 shares for transaction amount of $6,200 was made by Devi Nandini () on 2022‑05‑20.

List of Insider Buy and Sell Transactions, IRIDEX Corporation

2022-05-20Purchase
2,000
0.0126%
$3.10$6,200-24.68%
2022-03-16Purchase
2,000
0.0122%
$4.20$8,400-41.86%
2021-12-02Purchasedirector
1,644
0.0102%
$6.08$9,999-49.59%
2021-11-16Purchasedirector
1,000
0.0064%
$7.73$7,730-56.27%
2020-05-15Purchasedirector
15,125
0.1082%
$1.68$25,446+44.22%
2019-11-18Purchasedirector
14,600
0.0911%
$2.04$29,749+0.49%
2019-11-15Purchasedirector
10,000
0.0625%
$2.02$20,187+1.49%
2019-11-14Purchasedirector
10,000
0.0625%
$2.02$20,200+1.49%
2019-11-13Purchasedirector
5,000
0.0311%
$2.01$10,050+1.49%
2018-12-13Purchasedirector
863
0.0054%
$4.30$3,711-0.82%
2018-12-12PurchaseChairman and CEO
10,000
0.0642%
$4.34$43,443+0.59%
2018-12-12Purchasedirector
3,684
0.0235%
$4.32$15,903+0.59%
2018-12-11Purchasedirector
4,673
0.0298%
$4.18$19,542+3.78%
2018-12-10Purchasedirector
2,500
0.0156%
$4.17$10,432+1.55%
2018-11-27PurchaseChairman and CEO
10,000
0.062%
$4.71$47,144-8.11%
2018-09-18Purchase
70,000
0.4375%
$6.00$420,000-22.00%
2018-09-14PurchaseChairman and CEO
10,000
0.0613%
$6.56$65,600-29.97%
2018-03-13Sale
2,806
0.0166%
$5.86$16,444-6.77%
2017-12-12PurchaseChairman and CEO
5,000
0.0318%
$7.84$39,200-15.82%
2017-09-15PurchaseChairman and CEO
1,800
0.0109%
$9.42$16,956-23.20%

Insider Historical Profitability

4.28%
BlueLine Catalyst Fund IX, L.P.
2559122
15.3827%
$1.59180+10.43%
BlueLine Capital Partners II, L.P.10 percent owner
2508100
15.076%
$1.5920+27.27%
BlueLine Partners, L.L.C.10 percent owner
2465222
14.8182%
$1.5990
Acuta Capital Fund, LP10 percent owner
1344720
8.083%
$1.59330<0.0001%
PARAGON ASSOCIATES & PARAGON ASSOCIATES II JOINT VENTURE
1320000
7.9344%
$1.59170+39.25%

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Paragon Associates Paragon Associates Ii Joint Venture$2.98M6.151M0%+$05.31
The Vanguard Group$1.67M3.45561,096+0.7%+$11,613.06<0.0001
Amh Equity Ltd$1.36M2.81456,400+15.25%+$179,992.001.76
Renaissance Technologies$1.22M2.52410,160-1.18%-$14,598.69<0.01
Geode Capital Management$359,765.000.74120,6940%+$0<0.0001
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.